Non-Alcoholic Fatty Liver Disease

Detailed Overview

It is the hepatic manifestation of metabolic syndrome. The condition progresses when simple steatosis is subjected to oxidative stress and lipotoxicity, triggering inflammation (NASH/MASH). Chronic inflammation activates hepatic stellate cells, which deposit collagen and cause fibrosis. It is rapidly becoming the leading indication for liver transplantation worldwide and increases the risk for hepatocellular carcinoma even before cirrhosis develops.

Epidemiology & Demographics

Global prevalence is estimated at 25-30%. It affects up to 70-90% of individuals with obesity or type 2 diabetes. Hispanics have the highest prevalence in the US.

Etiological Mechanism

Driven by systemic insulin resistance and dyslipidemia in the setting of excess caloric intake. Genetic polymorphisms, notably in the PNPLA3 gene, strongly predispose individuals to hepatic fat accumulation.

Primary Causes

Insulin resistance leading to increased free fatty acid flux to the liver, increased de novo lipogenesis, and decreased beta-oxidation.

• Obesity: Central adiposity is the strongest independent risk factor.
• Type 2 Diabetes Mellitus: T2DM accelerates progression to NASH and advanced fibrosis.
• Dyslipidemia: High triglycerides and low HDL cholesterol.

The 'two-hit' or 'multiple-hit' hypothesis. Hit 1: Insulin resistance causes peripheral lipolysis, flooding the liver with free fatty acids (FFAs). The liver packages these into triglycerides, causing steatosis. Hit 2: Lipotoxicity from specific lipid species (e.g., ceramides, diacylglycerols) causes mitochondrial dysfunction and oxidative stress. This induces hepatocyte apoptosis, releasing damage-associated molecular patterns (DAMPs) that activate Kupffer cells. The ensuing inflammatory cascade activates hepatic stellate cells, which transform into myofibroblasts and deposit extracellular matrix (fibrogenesis).

Characteristic Clinical Presentation

• Asymptomatic: Most patients are completely asymptomatic in early stages.
• Fatigue: Nonspecific tiredness is the most common complaint.
• Right Upper Quadrant discomfort: A dull ache resulting from stretching of the hepatic capsule due to hepatomegaly.

Physical Examination Signs

• Hepatomegaly on abdominal palpation.
• Acanthosis nigricans indicating severe insulin resistance.
• Signs of portal hypertension (splenomegaly, ascites, spider angiomata) if progressed to cirrhosis.

• Cirrhosis and Liver Failure: End-stage liver disease requiring transplant.
• Hepatocellular Carcinoma (HCC): Can occur in NASH even without established cirrhosis.
• Cardiovascular Disease: The most common cause of death in NAFLD patients.

Diagnostic Criteria & Guidelines

Requires imaging or histologic evidence of hepatic steatosis (>= 5% of hepatocytes) AND absence of significant alcohol consumption (<21 standard drinks/week for men, <14 for women) AND absence of competing etiologies (e.g., viral hepatitis, steatogenic drugs like amiodarone).

Differential Diagnosis

• Alcoholic Liver Disease
• Chronic Hepatitis B or C
• Autoimmune Hepatitis
• Wilson Disease

Laboratory Tests & Biomarkers

• AST/ALT Ratio: ALT usually higher than AST; ratio < 1 (reverses when cirrhosis develops). AST/ALT typically < 2-3x upper limit of normal.
• Fasting Lipid Panel: Elevated triglycerides (>150 mg/dL), low HDL (<40 mg/dL in men).
• FIB-4 Index: Calculated score using Age, AST, ALT, and Platelets to non-invasively estimate fibrosis risk.

Imaging Modalities & Findings

• Abdominal Ultrasound:
• Vibration-Controlled Transient Elastography (FibroScan):

• NAFL (Simple Steatosis)
  Hepatic steatosis without evidence of hepatocellular injury or ballooning. Minimal risk of progression to cirrhosis.
• NASH (Steatohepatitis)
  Hepatic steatosis with inflammation and hepatocyte ballooning. High risk for progressive fibrosis.
• NASH Cirrhosis
  Extensive scarring forming nodules, leading to loss of liver function and portal hypertension.

Second-Line & Adjunctive Therapy

GLP-1 receptor agonists (e.g., Semaglutide 2.4 mg SQ weekly) for weight management and metabolic control. Pioglitazone (30 mg PO daily) can improve histology in biopsy-proven NASH. Resmetirom (THR-beta agonist) recently FDA approved for NASH with F2-F3 fibrosis.

Surgical & Procedural Management

Bariatric surgery (e.g., Roux-en-Y gastric bypass) for eligible patients (BMI > 35 with comorbidities) is highly effective at resolving NASH. Liver transplantation for decompensated cirrhosis.

Recommended Lifestyle Changes

• Complete abstinence from alcohol to avoid synergistic liver damage.
• Eliminate fructose-sweetened beverages (soda, juice) which potently drive hepatic lipogenesis.
• Drink 2-3 cups of black coffee daily, which is associated with reduced hepatic fibrosis.

Patient Counseling & Advice

Emphasize that the condition is reversible in early stages with significant lifestyle changes. Warn that cardiovascular disease is their highest mortality risk, emphasizing the need for blood pressure and lipid control.

Follow-Up & Monitoring Schedule

Reassess metabolic risk factors every 6 months. Non-invasive fibrosis testing (FIB-4 or FibroScan) every 1-2 years. If cirrhotic, HCC screening with ultrasound every 6 months.

Preventive Strategies

Maintaining a healthy body mass index (BMI 18.5-24.9), routine screening for and management of diabetes and hyperlipidemia.

NAFL has a generally benign hepatic prognosis, but high cardiovascular risk. NASH with advanced fibrosis (F3/F4) has a high risk of progression to end-stage liver disease and significantly reduced life expectancy.